Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: Ramipril versus valsartan

Blood Purification

Volumn 25, Issue 4, 2007, Pages 327-335

  Yilmaz, Mahmut Ilker ^a,b   Saglam, Mutlu ^a   Sonmez, Alper ^a   Caglar, Kayser ^a   Cakir, Erdinc ^a   Kurt, Yasemin ^a   Eyileten, Tayfun ^a   Tasar, Mustafa ^a   Acikel, Cengizhan ^a   Oguz, Yusuf ^a   Vural, Abdulgaffar ^a   Yenicesu, Mujdat ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Asymmetric dimethylarginine; Proteinuria; Ramipril; Valsartan

Indexed keywords

ARGININE; ARGININE DERIVATIVE; C REACTIVE PROTEIN; INSULIN; N(G),N(G) DIMETHYLARGININE; PROTEIN; RAMIPRIL; SYMMETRIC DIMETHYLARGININE; UNCLASSIFIED DRUG; VALSARTAN;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FEMALE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL; PROTEINURIA; STATISTICAL SIGNIFICANCE;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARGININE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; FEMALE; GLOMERULAR FILTRATION RATE; HEMORHEOLOGY; HUMANS; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; LIPIDS; MALE; MIDDLE AGED; PROTEINURIA; RAMIPRIL; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; VALINE; VASODILATION;

EID: 34548827668     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107410     Document Type: Article

References (38)

1. Vallance P, Leone A, Calver A, et al: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-575.
2. Boger RH: Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 2006;38:126-136.
3. Zoccali C: Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. J Hypertens 2006;24:611-619.
4. Kielstein JT, Impraim B, Simmel S, et al: Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004;109:172-177.
5. Kielstein JT, Simmel S, Bode-Boger SM, et al: Suppressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press Res 2004;27:143-147.
6. Persson PB: Nitric oxide in the kidney. Am J Physiol 2002;283:R1005- R1007.
7. Remuzzi G, Perico N, Macia M, et al: The role of renin-angiotensin- aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 2005;S57-S65.
8. Chen JW, Hsu NW, Wu TC, et al: Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol 2002;90:974-982.
9. Delles C, Schneider MP, John S, et al: Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens 2002;15:590-593.
10. Ito A, Egashira K, Narishige T, et al: Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus. Circ J 2002;66:811-815.
11. Napoli C, Sica V, de Nigris F, et al: Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004;148:e5.
12. Matthews DR, Hosker JP, Rudenski AS, et al: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
13. Chen BM, Xia LW, Zhao RQ: Determination of N(G),N(G)-dimethylarginine in human plasma by high-performance liquid chromatography. J Chromatogr [B] 1997;692:467-471.
14. Levey AS, Bosch JP, Lewis JB, et al: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
15. Celermajer DS, Sorensen KE, Gooch VM, et al: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-1115.
16. Leiper JM, Santa Maria J, Chubb A, et al: Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999;343/1:209-214.
17. Ogawa T, Kimoto M, Sasaoka K: Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 1989;264:10205-10209.
18. Caglar K, Yilmaz MI, Sonmez A, et al: ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int 2006;70:781-787.
19. Kielstein JT, Boger RH, Bode-Boger SM, et al: Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002;13:170-176.
20. Kielstein JT, Zoccali C: Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? Am J Kidney Dis 2005;46:186-202.
21. Suda O, Tsutsui M, Morishita T, et al: Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 2004;24:1682-1688.
22. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-1863.
23. Aranda P, Segura J, Ruilope LM, et al: Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am J Kidney Dis 2005;46:1074-1079.
24. Hilgers KF, Mann JF: ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol 2002;13:1100-1108.
25. Maschio G, Alberti D, Janin G, et al: Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996;334:939-945.
26. Remuzzi A, Perico N, Sangalli F, et al: ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol 1999;276:F457-F466.
27. Fliser D, Wagner KK, Loos A, et al: Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005;16:1135-1140.
28. Aslam S, Santha T, Leone A, et al: Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int 2006;70:2109-2115.
29. Cooke JP: Asymmetrical dimethylarginine: the Uber marker? Circulation 2004;109:1813-1818.
30. Boger RH, Ron ES: L -Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev 2005;10:14-23.
31. Boger RH, Bode-Boger SM, Brandes RP, et al: Dietary L -arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation 1997;96:1282-1290.
32. Boger RH, Bode-Boger SM, Thiele W, et al: Restoring vascular nitric oxide formation by L -arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 1998;32:1336-1344.
33. Kielstein JT, Salpeter SR, Bode-Boeger SM, et al: Symmetric dimethylarginine (SDMA) as endogenous marker of renal function: a meta-analysis. Nephrol Dial Transplant 2006;21:2446-2451.
34. McDermott JR: Studies on the catabolism of Ng-methylarginine, Ng, Ng-dimethylarginine and Ng, Ng-dimethylarginine in the rabbit. Biochem J 1976;154:179-184.
35. Yilmaz MI, Saglam M, Caglar K, et al: The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 2006;47:42-50.
36. Fenster BE, Tsao PS, Rockson SG: Endothelial dysfunction: clinical strategies for treating oxidant stress. Am Heart J 2003;146:218-226.
37. Wolf G, Ritz E: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005;67:799-812.
38. Hu T, Chouinard M, Cox AL, et al: Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylamino-hydrolase-1 gene regulation. J Biol Chem 2006;281:39831-39838.